These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32718999)

  • 1. Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts.
    Mehta RK; Pal S; Kondapi K; Sitto M; Dewar C; Devasia T; Schipper MJ; Thomas DG; Basrur V; Pai MP; Morishima Y; Osawa Y; Pratt WB; Lawrence TS; Nyati MK
    Clin Cancer Res; 2020 Oct; 26(19):5246-5257. PubMed ID: 32718999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological Inhibition of HSP90 Radiosensitizes Head and Neck Squamous Cell Carcinoma Xenograft by Inhibition of DNA Damage Repair, Nucleotide Metabolism, and Radiation-Induced Tumor Vasculogenesis.
    Naz S; Leiker AJ; Choudhuri R; Preston O; Sowers AL; Gohain S; Gamson J; Mathias A; Van Waes C; Cook JA; Mitchell JB
    Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1295-1305. PubMed ID: 33838214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells.
    Spiegelberg D; Dascalu A; Mortensen AC; Abramenkovs A; Kuku G; Nestor M; Stenerlöw B
    Oncotarget; 2015 Nov; 6(34):35652-66. PubMed ID: 26452257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma model.
    Spiegelberg D; Mortensen AC; Selvaraju RK; Eriksson O; Stenerlöw B; Nestor M
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):974-982. PubMed ID: 26627081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.
    Smyth T; Van Looy T; Curry JE; Rodriguez-Lopez AM; Wozniak A; Zhu M; Donsky R; Morgan JG; Mayeda M; Fletcher JA; Schöffski P; Lyons J; Thompson NT; Wallis NG
    Mol Cancer Ther; 2012 Aug; 11(8):1799-808. PubMed ID: 22714264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach.
    Spiegelberg D; Abramenkovs A; Mortensen ACL; Lundsten S; Nestor M; Stenerlöw B
    Sci Rep; 2020 Apr; 10(1):5923. PubMed ID: 32246062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer.
    Graham B; Curry J; Smyth T; Fazal L; Feltell R; Harada I; Coyle J; Williams B; Reule M; Angove H; Cross DM; Lyons J; Wallis NG; Thompson NT
    Cancer Sci; 2012 Mar; 103(3):522-7. PubMed ID: 22181674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TAS-116, a Novel Hsp90 Inhibitor, Selectively Enhances Radiosensitivity of Human Cancer Cells to X-rays and Carbon Ion Radiation.
    Lee Y; Sunada S; Hirakawa H; Fujimori A; Nickoloff JA; Okayasu R
    Mol Cancer Ther; 2017 Jan; 16(1):16-24. PubMed ID: 28062703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation.
    Chan KC; Ting CM; Chan PS; Lo MC; Lo KW; Curry JE; Smyth T; Lee AW; Ng WT; Tsao GS; Wong RN; Lung ML; Mak NK
    Mol Cancer; 2013 Oct; 12(1):128. PubMed ID: 24156782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors.
    Shapiro GI; Kwak E; Dezube BJ; Yule M; Ayrton J; Lyons J; Mahadevan D
    Clin Cancer Res; 2015 Jan; 21(1):87-97. PubMed ID: 25336693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors.
    Do K; Speranza G; Chang LC; Polley EC; Bishop R; Zhu W; Trepel JB; Lee S; Lee MJ; Kinders RJ; Phillips L; Collins J; Lyons J; Jeong W; Antony R; Chen AP; Neckers L; Doroshow JH; Kummar S
    Invest New Drugs; 2015 Aug; 33(4):921-30. PubMed ID: 26082332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models.
    Smyth T; Paraiso KHT; Hearn K; Rodriguez-Lopez AM; Munck JM; Haarberg HE; Sondak VK; Thompson NT; Azab M; Lyons JF; Smalley KSM; Wallis NG
    Mol Cancer Ther; 2014 Dec; 13(12):2793-2804. PubMed ID: 25349308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.
    Canella A; Welker AM; Yoo JY; Xu J; Abas FS; Kesanakurti D; Nagarajan P; Beattie CE; Sulman EP; Liu J; Gumin J; Lang FF; Gurcan MN; Kaur B; Sampath D; Puduvalli VK
    Clin Cancer Res; 2017 Oct; 23(20):6215-6226. PubMed ID: 28679777
    [No Abstract]   [Full Text] [Related]  

  • 14. Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.
    Kang MH; Reynolds CP; Houghton PJ; Alexander D; Morton CL; Kolb EA; Gorlick R; Keir ST; Carol H; Lock R; Maris JM; Wozniak A; Smith MA
    Pediatr Blood Cancer; 2012 Jul; 59(1):185-8. PubMed ID: 21538821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
    Wagner AJ; Agulnik M; Heinrich MC; Mahadevan D; Riedel RF; von Mehren M; Trent J; Demetri GD; Corless CL; Yule M; Lyons JF; Oganesian A; Keer H
    Eur J Cancer; 2016 Jul; 61():94-101. PubMed ID: 27156227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of Heat Shock Protein 70 as a Predictive Marker of the Tumor Cell Radiosensitization with Inhibitors of the Heat Shock Protein 90 Activity.
    Kudryavtsev VA; Khokhlova V AV; Mosina A; Makarova YM; Kabakov AE
    Radiats Biol Radioecol; 2016 Sep; 56(5):494-502. PubMed ID: 30703309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors.
    Do KT; O'Sullivan Coyne G; Hays JL; Supko JG; Liu SV; Beebe K; Neckers L; Trepel JB; Lee MJ; Smyth T; Gannon C; Hedglin J; Muzikansky A; Campos S; Lyons J; Ivy P; Doroshow JH; Chen AP; Shapiro GI
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):815-827. PubMed ID: 33095286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.
    Stingl L; Stühmer T; Chatterjee M; Jensen MR; Flentje M; Djuzenova CS
    Br J Cancer; 2010 May; 102(11):1578-91. PubMed ID: 20502461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy.
    Xu J; Wu PJ; Lai TH; Sharma P; Canella A; Welker AM; Beattie CE; Elder JB; Easley M; Lonser R; Jacob NK; Pietrzak M; Timmers CM; Lang F; Sampath D; Puduvalli VK
    Clin Cancer Res; 2022 May; 28(9):1979-1990. PubMed ID: 35140124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage.
    Zaidi S; McLaughlin M; Bhide SA; Eccles SA; Workman P; Nutting CM; Huddart RA; Harrington KJ
    PLoS One; 2012; 7(4):e35436. PubMed ID: 22523597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.